Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus
An FDA-approved GLP-1 receptor agonist that produces significant weight loss (average 14.9% body weight in clinical trials). One of the most clinically validated weight loss peptides available.
Mechanism of Action
Semaglutide activates GLP-1 receptors in the pancreas, brain, and GI tract. The resulting appetite suppression and reduced caloric intake drive substantial weight loss.
Amino Acid Sequence (31 AAs)
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂ (C18 fatty diacid chain via K34)
Benefits
- Average 14.9% body weight reduction in clinical trials
- Potent appetite suppression
- Blood glucose regulation
- Cardiovascular risk reduction
- Improved metabolic markers
- Reduced visceral fat
- Weekly dosing convenience
Side Effects & Risks
- Nausea (most common, especially early)
- Constipation or diarrhea
- Vomiting
- Abdominal pain
- Potential pancreatitis (rare)
- Muscle mass loss with rapid weight loss
Where to Buy Semaglutide
4 options across 3 vendors · Sorted cheapest first · All include direct product link
From
$68.00
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C or room temp reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water), do not freeze reconstituted
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies4 trials
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity.
SELECT: Cardiovascular Outcomes with Semaglutide in Obesity without Diabetes
In 17,604 adults with obesity and cardiovascular disease (no T2D), semaglutide 2.4mg reduced MACE by 20% vs placebo (HR 0.80, 95% CI 0.72-0.90; p<0.001) over mean 33.9 months.
Primary Outcome
MACE (cardiovascular death, non-fatal MI, non-fatal stroke)
95% CI
0.72 to 0.90
p-value
<0.001
Weight Loss
-9.4% sema vs -0.9% placebo
Hazard Ratio
0.80
Absolute Risk Reduction
6.5% vs 8.0%
STEP 1: Semaglutide 2.4mg vs Placebo in Adults with Obesity
In 1,961 adults without T2D, once-weekly semaglutide 2.4mg produced mean weight loss of 14.9% vs 2.4% for placebo at 68 weeks (p<0.001). 86.4% of semaglutide vs 31.5% of placebo participants lost ≥5% body weight.
Primary Outcome
Weight change from baseline
95% CI
-13.4 to -11.5
p-value
<0.001
Placebo Result
-2.4%
≥5% Responders
86.4% (sema) vs 31.5% (placebo)
≥10% Responders
69.1% vs 12.0%
≥15% Responders
50.5% vs 4.9%
≥20% Responders
32.0% vs 1.7%
Semaglutide Result
-14.9%
Treatment Difference
-12.4 percentage points
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Semaglutide 2.4mg weekly produced mean weight reduction of 14.9% over 68 weeks.
p-value
<0.001
Weight Loss
14.9%
Molecular Structure
- CAS Number
- 910463-68-2
- PubChem CID
- 56843331
- Molecular Weight
- 4,114 Da
- Mol. Formula
- C187H291N45O59
- Amino Acids
- 31-AA peptide
- Wikipedia
- View article
Research Protocol
- Dose Range
- 0.25–2.4 mg
- Frequency
- Once weekly subcutaneous injection
- Cycle
- Ongoing / chronic
- Half-Life
- 7 days
- Routes
- subcutaneous injectionoral
- Notes
- Start at 0.25mg/week, titrate up over 16-20 weeks to target dose.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
More in Weight Management
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.